Mal-PEG8-Phe-Lys-PAB-Exatecan (TFA)
Product Specifications
UNSPSC Description
Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631)[1].
Target Antigen
Drug-Linker Conjugates for ADC; Topoisomerase
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mal-peg8-phe-lys-pab-exatecan-tfa.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C=CC1=O)N1CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCCN)C(NC(C=C3)=CC=C3COC(N[C@@H]4C5=C6C(C(N7C6)=CC([C@](O)(C(OC8)=O)CC)=C8C7=O)=NC9=CC(F)=C(C)C(CC4)=C95)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
Molecular Weight
1548.58
References & Citations
[1]Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1. |[2]Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1.
Shipping Conditions
Blue Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-148380A/Mal-PEG8-Phe-Lys-PAB-Exatecan-TFA-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-148380A/Mal-PEG8-Phe-Lys-PAB-Exatecan-TFA-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
